Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Role of TLRs in Anti-cancer Immunity and Tumor Rejection

Z. Urban-Wojciuk, MM. Khan, BL. Oyler, R. Fåhraeus, N. Marek-Trzonkowska, A. Nita-Lazar, TR. Hupp, DR. Goodlett,

. 2019 ; 10 (-) : 2388. [pub] 20191022

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028784

Grantová podpora
1R01AI123820-01 NIAID NIH HHS - United States

In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.

000      
00000naa a2200000 a 4500
001      
bmc20028784
003      
CZ-PrNML
005      
20210114155140.0
007      
ta
008      
210105s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2019.02388 $2 doi
035    __
$a (PubMed)31695691
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Urban-Wojciuk, Zuzanna $u International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland.
245    14
$a The Role of TLRs in Anti-cancer Immunity and Tumor Rejection / $c Z. Urban-Wojciuk, MM. Khan, BL. Oyler, R. Fåhraeus, N. Marek-Trzonkowska, A. Nita-Lazar, TR. Hupp, DR. Goodlett,
520    9_
$a In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.
650    _2
$a adaptorové proteiny signální transdukční $x metabolismus $7 D048868
650    _2
$a zvířata $7 D000818
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    12
$a imunita $7 D007109
650    _2
$a ligandy $7 D008024
650    _2
$a nádory $x etiologie $x metabolismus $x patologie $x terapie $7 D009369
650    _2
$a orgánová specificita $x genetika $x imunologie $7 D009928
650    _2
$a vazba proteinů $7 D011485
650    _2
$a toll-like receptory $x agonisté $x genetika $x metabolismus $7 D051193
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Khan, Mohd M $u Laboratory of Immune System Biology (LISB), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States. University of Maryland School of Medicine, Baltimore, MD, United States.
700    1_
$a Oyler, Benjamin L $u University of Maryland School of Medicine, Baltimore, MD, United States.
700    1_
$a Fåhraeus, Robin $u International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland. Department of Medical Biosciences, Umeå University, Umeå, Sweden. Université Paris 7, INSERM, UMR 1162, Paris, France. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia.
700    1_
$a Marek-Trzonkowska, Natalia $u International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland. Laboratory of Immunoregulation and Cellular Therapies, Department of Family Medicine, Medical University of Gdaǹsk, Gdaǹsk, Poland.
700    1_
$a Nita-Lazar, Aleksandra $u Laboratory of Immune System Biology (LISB), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.
700    1_
$a Hupp, Ted R $u International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia. Cell Signaling Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
700    1_
$a Goodlett, David R $u International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland. Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, United States.
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 10, č. - (2019), s. 2388
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31695691 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155138 $b ABA008
999    __
$a ok $b bmc $g 1609119 $s 1119964
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 2388 $e 20191022 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
GRA    __
$a 1R01AI123820-01 $p NIAID NIH HHS $2 United States
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace